The Rochester Clinical and Translational Science Award (RCTSA) Program proposes continuation of its dual goals: 1) To organize, support, and expand clinical and translational research at the University of Rochester within an academic home, the University of Rochester Clinical and Translational Science Institute (URCTSI), and 2) To integrate and collaborate with regional and national institutions to expand a National Clinical and Translational Research Network. The RCTSA Program has truly transformed the University of Rochester Medical Center (URMC), with the construction of a state-of-the-art Clinical and Translational Science Building, the integration of clinical and translational science into the shared vision for URMC research, a successful system of dynamic governance, expansion of research resources, and enthusiastic participation and leadership in the National CTSA Consortium. To continue this momentum, the UR-CTSI will carry out a number of specific aims. First, three new key functions will be implemented: Public-Private Partnerships, Tl Translation, and Comparative Effectiveness Research. Existing Key Functions will be reorganized and consolidated to provide better support of investigators by an expanded Office of Regulatory Support, a Navigator/Consultation Service, and an Incubator Program consolidating Pilot Studies, Novel Methodologies, and Translational Technologies Key Functions. The CTSI will establish and foster four centers of research excellence across the spectrum of research translation: Center for Human Experimental Therapeutics (Tl Research);Clinical Research Center (T1-3 Research);Center for Research Implementation and Translation (T2-3 research under School of Nursing sponsorship);and Center for Community Health (T2-3 research). A broad range of education, training, and career development programs will continue to meet research workforce needs. The UR-CTSI will be an active participant in the National CTSA consortium with sharing of expertise, methods, data, and curricula. The Upstate New York Translational Research Network (UNYTRN) will be expanded to support the region's biomedical research institutions. Finally, the UR-CTSI will be evaluated through the measurement of rigorous performance outcomes.
The UR Clinical and Translational Science Institute (UR-CTSI) will be the focal point for translation of basic discoveries to human applications and clinical trials, and for evidence-based implementation of efficacious clinical practices and effective community strategies. The UR CTSI will be a model for CTSA involvement of nursing, dentistry, and other disciplines, for engagement ofthe Rochester community in all aspects of research and for collaboration with regional biomedical institutions in research translation.
|Xu, Wei; Wang, Hui-Fu; Tan, Lin et al. (2016) The impact of PICALM genetic variations on reserve capacity of posterior cingulate in AD continuum. Sci Rep 6:24480|
|Tan, Lin; Wang, Hui-Fu; Tan, Meng-Shan et al. (2016) Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer's disease cohorts. Sci Rep 6:26027|
|Shokouhi, Sepideh; Mckay, John W; Baker, Suzanne L et al. (2016) Reference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment. Alzheimers Res Ther 8:2|
|Shum, Laura C; White, Noelle S; Nadtochiy, Sergiy M et al. (2016) Cyclophilin D Knock-Out Mice Show Enhanced Resistance to Osteoporosis and to Metabolic Changes Observed in Aging Bone. PLoS One 11:e0155709|
|Hua, Xue; Ching, Christopher R K; Mezher, Adam et al. (2016) MRI-based brain atrophy rates in ADNI phase 2: acceleration and enrichment considerations for clinical trials. Neurobiol Aging 37:26-37|
|Mormino, Elizabeth C; Sperling, Reisa A; Holmes, Avram J et al. (2016) Polygenic risk of Alzheimer disease is associated with early- and late-life processes. Neurology 87:481-8|
|Shum, Laura C; White, Noelle S; Mills, Bradley N et al. (2016) Energy Metabolism in Mesenchymal Stem Cells During Osteogenic Differentiation. Stem Cells Dev 25:114-22|
|Zhang, Deng-Feng; Li, Jin; Wu, Huan et al. (2016) CFH Variants Affect Structural and Functional Brain Changes and Genetic Risk of Alzheimer's Disease. Neuropsychopharmacology 41:1034-45|
|Yang, Yaoli Pu; Lotta, Louis; Beutner, Gisela et al. (2016) Induction of Expression of p75 Neurotrophin Receptor Intracellular Domain Does Not Induce Expression or Enhance Activity of Mitochondrial Complex II. Oxid Med Cell Longev 2016:8752821|
|Zhang, Xiuming; Mormino, Elizabeth C; Sun, Nanbo et al. (2016) Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer's disease. Proc Natl Acad Sci U S A 113:E6535-E6544|
Showing the most recent 10 out of 93 publications